The value of medicines dispensed to patients in Romania rose by 22.8 percent year-on-year in the first quarter of this year up to RON 4.64 billion (EUR 980.6 million), while Merck replaced AbbVie as market leader, according to report released by Cegedim.
Drugs related to cost-volume increased by 37 percent and those for cost-volume-result contracts increased by 184.8 percent.
The rest of retail Rx (prescription-based medicines) market increased by 6.8 percent, as compared to Q1 2018. By segments, the increase rates in values were of 23.1 percent for Rx in pharmacies, 20.2 percent for OTC in pharmacies and 26.8 percent in hospitals.
Between April 2018 and March 2019, the total value of the market was of RON 16.93 bn, up by 15.3 percent, as compared to April 2017 – March 2018.
Prescription-based medicines from pharmacies reached RON 11.23 bn (+14.8 percent), over-the-counter medicines (OTC) from pharmacies scored RON 3.71 bn (+16.3 percent), and the hospital segment attained the value of RON 2.0 bn (+16.6 percent).
The structure of the 3 leading corporations from a value point of view, in the recent 12 months changes as result of the significant growth of medicines allocated to cost – volume – result contracts (for interferon free therapy for hepatitis C).
In Q1 2019, Merck was the market leader in Romania by value of sales (RON 318.8 million), followed by AbbVie (RON 253.1 million) and Gilead (RON 233.5 million).
Thus, AbbVie occupies the first position with sales of RON 1.08 billion, followed by Merck with RON 950.4 million and Sanofi with RON 848.9 million.
The top 10 players also include Novartis (with Sandoz) with sales of RON 726.6 million, followed by Servier (including Egis) with RON 684.6 million, GlaxoSmithKline (RON 675.3 million), Sun Pharma (including Terapia) RON 647.9 million, Pfizer (RON 625.8 million), AstraZeneca (RON 565.3 million) and Bristol Myers Squibb (RON 517.9 million).
These data estimate pharmaceutical products dispensed from pharmacies to patients, the estimation of the above values and market shares being made in pharmacy purchase prices.
These data do not constitute information about the turnover and profit margins of drug manufacturers present in Romania, nor can they be extrapolated to this, due to the specific internal market regulation framework.